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WC report the cloning of a rat cDNA encoding a functional dopdminc transporter. This cDNA. derived from an intron-containing Scnc. encodes 
a protein of 620 ammo acids. Hydropathicity analysis of the protein scqucncc suggests the prcscncc of 12 putative transmcmbrane domains. The 
protein displays considcrablc identity with transporters ror noradrcnalinc and GABA (64 and 30%. respcctivcly). Transient cxprcssion ofthecDNA 
in COS7 cells directs the cxprcssion of dopdtninc uptake activity with appropriate phartnacology and in a sodium-dcpcndcnt fashion. In situ 
hybridization reveals that the mRNA Ibr this transporter is cxprcsscd in the substantia nigra and ventral tegmcntal ar.ea, regions that contain 
dopaminergic cell bodies. 
Dopaminc transporter; Transmembranc domain; Substantia nigra pars compacta; Ventral rcgmental 
1, INTRODUCTION 
Neurotransmission is a complex phenomenon involv- 
ing the interplay of several processes. These various 
systems include: (i) the synthesis, storage and release of 
the neurotransmitter; (ii) the interaction of the neuro- 
transmitter with specific receptors located on both pre- 
and postsynaptic terminals; and (iii) the rapid removal 
of the transmitter, and termination of its action via 
enzymatic degradation or via specialized transporter 
proteins on presynaptic terminals [I]. 
Whereas many of the protein components and mech- 
anisms involved in the synthesis and receptor-mediated 
effects of neurotransmitters have been fairly well stud- 
ied, the biochemical and molecular details of termina- 
tion processes have been mostly unknown. The uptake 
of neurotransmitters uch as noradrenaline, dopamine 
and serotonin is mediated by a Na’-dependent process 
[2] and seems to represent he most important pathway 
for cessation of the action of these monoamines. For 
example, 80-90% of noradrenaline is removed from the 
synapse into nerve terminals by a specific noradrenaline 
uptake mechanism [3], as opposed to being degraded by 
metabolizing enzymes such as monoamine oxidase or 
catechol-O-methyl transferase [3]. The importance of 
uptake mechanisms in the synaptic function is further 
highlighted by the large number and dramatic pharma- 
cological effects of drugs that interact with these trans- 
porter proteins, such as anti-depressants and substances 
of abuse such as cocaine and amphetamine. Dopamine 
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uptake i.s related, for example, to locomotor activity, 
positive reinforcement and cocaine self-administration 
[4]. Because of the potential involvement of the dopami- 
nergic neurotransmission system in the etiology of psy- 
chiatric disorders or neurological diseases, elucidation 
of the molecular properties of the dopamine transporter 
could provide new and powerful means to understand 
these mechanisms and develop novel therapeutic tools. 
The recent biochemical purification of a brain y- ami- 
nobutyric acid (GABA) transporter [5] and the develop- 
ment of expression cloning techniques for these proteins 
[6,7] has led to the elucidation of the structure of 2 
members of this transporter protein family, one for 
GABA and another selective for the biogenic amine 
noradrenaline (NA) [8,9]. These proteins are single po- 
lypeptides of -600 amino acids, characterized ‘by :he 
presence within their sequence of 12 hydrophobic stret- 
ches of 20-25 amino acids that may represent trans- 
membrane domains [8,9]. In that respect, these proteins 
tXSriii’irl82 tliz ATT-diiVCi3 nm! nutrient families of trans- 
porter proteins [lO,l 11. However, their primary struc- 
ture clearly indicates that they define a unique family of 
transmembrane proteins. Within several of their trans- 
membrane domains, the NA and GABA transporters 
display significant (~46%) amino acid identities. Neuro- 
transmitter transporters are synthesized within the same 
neurons that synthesize their neurotransmittcrs. Thus, 
for the dopaminergic, noradrenergic and scrotonergic 
systems, mRNA for these transporters would be ex- 
pected to show a distribution essentially restricted to 
these particular cell bodies. Based on these premises, it 
was surmised that the use of dcgencrate oligonuclcotide 
primers from conserved regions of known transporters 
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~CCTCCASTCTACCC ATG AC?’ AAG AK AAh TGC ‘XC GTG CrA 
IdE? se; Lys SCT 
.I CCA ATC XT TCA CTG GTC GCC CCG CC’? AM GAS 
Lys cys ser vai 
. 
t:y ?ro Ker_ Ser Sdr Val Val Ala Pro Ala Lys C!u 
‘KC AAT CC? C’K GX CCC ACh GAG C’iG GAG CTC ATC CTG SC AAG GhG CAG AAC CGA GTG CAG CTG ACC AAC TCC ACC C'X 
ser Asn Aia Vai Gly P-0 Arg G?u Val Glu Lel; Zle Leti Val Lys GEE Glr. Asr. Gly Val Gin Leu Thr .Isr. Ser l’hr TCU 
l 
h’rc AX CCC CCA CAG ACA CCA KG GAG GCT CA,? GAG CCG GAG ACC TGS AGC AAG Afd IAT? Ghf TTC CTG CTA I-CA CTC ATC 
Ilc Asn Pro Prc Gin :nr PKD Vel Clu Ala Glr. Clu Arg G11! ?hr Trp Scr Lys Lys Ile Asp Phc Leti Lcl: Ser Val Ile 
l 
GCC TTT GCT G,G GAC CTC, GCC AAT GTC TGG AtG ?TT CCC TAC CTG TGC TAC AAA AAT GGT 
4 
CGA GGT GCC ?TC CTG GTG CCC 
Cl,' Phe Ala Va! Asp Le:: Alz Asn Val Trp Aeq Phc Pro Tyr Lel: Cys Tyr 'ys Asn Gly GLy GLy Ala Phe Lcu Va: Pro 
'TAC CTG C,C TTC ATG CT: ATT CC? GGG AT'- u CCC C,C TTC TAC ATG GAG CTC GCT CTC CGA CAG TX MC AGA GAA CGA XT 
Tyc Leti Leu PC@ WC: '.'a? Ilc Ala Cly Met Pro :eu Phc ?yr He: CLu l.eil Ala Leu Gly Glr. Phe Asn A-g G?u G!y Ala 
4 
GCT GCT G?C 7GG AAG KC TG7 CCT GTC CTG AAh GGT GTG CCC TTC ACT GTT frTC CTC ATC TCT TTC TAC CTG GGC TCC TTC 
A:a Gly Vai Trp Lys :lc Cys Pro Vai Le% 5ys Sly Val Gly Phe :h: Val Ile Lel: Ile Ser Phe Tyr Va? Gly Pha Pi:e 
TAC AA: GTC ATC AX CCli TGC GCA CT5 CirC TfrC TTC YTC XC XC YTC ACC ATG GAC CTC CCA ?GG ATC CAC TGC AAC MC 
7.1: nsn Vd? LlC :le A:a Trp Alil Le;: His Tyr Phs Phe Ser Scr FI:e Thr >Ic?c Asp Lc:: Pro Trp Ile HIS Cys Asn Asn 
ACC ?Gt BAT hGC CCC hfK TGC TCC GAY CCC CAT XC AGC AAC TCT AGC GAP GGC cx GGC cx AAT GAC Act TrT cc: ACC 
Ttr T-3 Asn Scr ?roa Asp Ala His Ala Ser Asn SCK Scr Asp G?y Le?r Gly ‘,eu Asn Aso Thr Phe Gly Thr 
a 
AC;! CCC GCT GCT GAG ?hC FTT CAG CC1’ GSC GTG ClG CAC CT: C,AC 'ZAG AGC CG: GGC ATT CAT GAC CTG GCC CCT CCA CCG 
‘:br FTZ h!o h!a .Glu :yr PhC Clu Arq Giy Vd! Seu 41s Leu ilis Glr. Ser Arg Gly I?e Asp Asp Leu Gly Pea Pm Arg 
TGG Cf>G CTC ACX XC IGC CTG GTC c-x xc ,wr ci-rT CTG cx ‘YrAC TX AGC CTA TSG fsAG 
T.-p G?z Lcu ‘3: 
CGA GTA AAG ACC TCA CCC AAG 
Ala cys Leu VAl Lou va: Ilc Val Lc;; Lel: Tyr Phe Ser Lcu Trp Lys Gly Val Lys Thr Sc~ Gly Lye 
l 
GTC GTC TCG ATC ACi\ GCT ACC ATG CCC TAT GTC XC CTC AC*\ XC CTG CTC CTG CGY’ 551: GTT ACC CTT CCT CGA GCC ATG 
Val Vai T_‘p Ile Thr A:a Thr t-:.x Pro 7yr Val Val Leu Tbr Ale LCI: Lea Lrv Arg Gly Va: ‘.“hz 5eu Pro tly Ala !?:et 
GA_ CGC i\TC AGA GCA TAC CX AGT G?G GAC TTC -AC CGA CTC TGT GAG GCA TCT GTG XC ATC CAT CC’? CCC AX CAG GTG 
Asp Gly Ile Arg Ala Ty: ieu Ser Val f,sp Phe Ty: Arg Leu Cys Glil Ala Ser VaL Trp 11-z frsp Ala Ala Thr Glr, Val 
TGC T?C ‘ICC CC GGC CT? GGG TTC GCA =TC CTC ATT CCC TTC XC AG” ?hC Ai\T 
CyS Phe Scr Lcu Gly Vnl Sly Phe Gly Va: 
AA.3 TX ACC AAT AX TGC TAT AGA GAC 
Lcu Ilc Ala ?kc SC.- Scr Tyr Asn Lys Phe Thr hsn Asn Cys Tyc Arg Asp 
* 
GCA f,TC AX ACC ACC TX ATT AAC ‘KC CTG ACA AGC TTC TCC TCT GGC 
ir?a I?@ !!c Ti.: Elr SC! Ilc ASE 
TTC GTC GTC TTC TCC TTC CTG GCG TAT ATC GCA 
Ser Lol: Thr See P.ic Scr Scr Gly Pho Val Val P!>e Ser ?I:o Lcu G?y Tyr Kcc hla 
CAG ;.,,C ChC AAT G-G Ccc AT:: f,cA CAT 3-G ~cc hch GAT GGA cCT CCC c7C ATC TTC f\TC AX TAT CCT GAG GCG ATC CCC 
C i !I Lys il:s Asn va: Pro :le fsrg Asp Va! f\lc> Thr Asp Cly Pro G?y Lcu 1:e ?he Ile 11s Tyr Pro Glu Ala Ile Ala 
ACA C'X CCG CTG TCY TCY' GCC TGG CC: GC: GTC TTC TX CTC A7G CTG CX AC: 
7ilr Leu ?r= !_eu scr Scr 
CTG CCT A'TC GtAC AGT GCA ATC GGG GGC 
A:a T.-p Ala Ala Val Phc Phc ',e~: MC: Les Leu T!?r Lou GLy Ile frsp Scr Ala Xec G!y Cly 
A*.‘= GAG 'XA GTG ATC AC7 GGC CTC GTC GA7 SAG TTC 
Xcc G?c icr Viii II@ 3r Sly 
CAG CTG CTA CAT CGG CAT CGA GAG CTC TX AC? CTT GGC ATT GTC 
TCE Vsl As? GII: P~c Girl LOU >@u tils Arg Kls Arg Glu Leti Phe The LOU G:.y !?o Vai 
C-X CCT AC- TTC CTG C'X XT CPC TTC TGC GTC f%CC APL GCC CGC 
Lc?:: ir1a 3; Phc !_eu Lcu scr 
ATC TAC GTC TX ACA CTG CTG GAC CAC TTT GCA GCT 
Le:: Pbc Cys Val Thr Asn Gly Giy IIti Ty: ‘.‘a1 Phn Thr Leu Lcil Asp iils The f,la Ala 
GGC A(-,., :‘CT ,P.,,‘;C CTC TTT (-CC ?TG cc rr-r of+, ccc AT7 GGG GTC cxc TCG YTC -xc GCC 
G:y Thr Scr :le Lc?r Pbe Ciy ;A1 Leu 110 Glr: Ala Ile Gly VJI Ala 
GTC CAG CAA PTC AGT GA? GAC 
T:,z Phe Tyr Gly Vai Gin Gin Pho .Scc Asp hsp 
AX AAG C,Af\ ATG hCA c;:G CAG CGA 
!ic Lys G!n Kc: ?hr 
CCC AAC CTG TAC TGC. CCC CTh PGC ;GG hAG CTG GTC AK CCC TCC TTC CTC C’TC “A7 
C!y Gin A.-g Pro frsn LCU Tyr Tep Arg !.cu Cys Trp Lys Lcu Val Scr Pro Cys Pi:@ Lcl; Leu Ty.- 
CTG GTC GTS GTC AGC A-2 KG ACC TX AGA CCC CCIA CAC TAT GCG GCC TAC AK TTC CCA GAC 
Vei Va? Vai Val Ser !le Val Thr Phc Arg Pro Pro His Tyr 
TGC CCC AAT CCC CTG CCC 
G:y Ala Tyr Ilc Phc ?ro Asp Trp Ala Asn Ala Lr.. Gly 
TGG hx xrc ccc ACA xc TCC fx GCC ATG GTG Ccc ATT TAT CCC ncc The AAG TTc TGC AGC 
‘Trp Ilc I?@ Ala Thr sor scr mc A:a !4eC Val Pro 1:~ Tyr Ala Thr Tyr Lys Phc Cys Ser 
l 
CTG CCC GCG TCC TTC CGO 
ICU Pro Gly Scr Pho Arg 
m 
ChC f,f,f\ CTC GCC TAT CCC AX ACh CC’: AAG AnA GAC CA’: CAG CTA GTG GAC AGA CGC GAG G’X 
Giu Lys Lot Ala Tyc A:a Ile Th: P-0 Lyo Lys Asp His 
* 
Cln Lcil Vnl Asp Arq G:y G?u Vol 
CCC CA.4 TTC KC CTC CGT 
Acy Gin Phe Thr Lel; hrg 
l 
iE57 
C;$C TCC C’rG TTG CTC ThA ASSGGAf~CCf~Gf~CfG--'C \ -. u 
ii!s ‘rrp h LCC LO:: sr0p 
CACC’~GGCCcACCTCf~CAf~CAGCGGGGAC~~GGGACATCCCAAAGGAAACCCACGACTCf~i~GGAA 
60 
20 
141 
47 
222 
74 
303 
101 
384 
128 
465 
:55 
546 
182 
627 
209 
708 
236 
789 
263 
870 
290 
951 
317 
1032 
344 
1113 
371 
1194 
398 
1275 
425 
356 
452 
1437 
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1518 
506 
1599 
533 
1680 
560 
1761 
507 
1842 
6i4 
1937 
619 
2046 
2153 
2218 
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could be used to amplify by polymerase chain reaction 
(PCR) partial cDNA c!ones from specific brain areas to 
obtain putative related members of this family. In this 
paper, we report using a partial PCR cDNA clone ob- 
tained from the substantia nigra, the cloning and char- 
acterization of a full length cDNA which encodes :I 
cocaine-sensitive brain dopamine transporter. 
2. MATERIALS AND METHODS 
Enzymes XXI in rccombin~nt DNA manipulations wcrc ohlaincd 
from Bochringcr and Promcga Biotcch. Chemicals wcrc from RBI 
(Nitlick. MA). Xlazindol and GBR 12783 were gilis from Dr. J.-J. 
Dot-act (Roucn. France!. whereas cocaine and I- and d-amphcraminc 
were obtained Tram Dr. E. Ellinwood (Duke University. NC). The 
cDNA library was a generous gift f’rom Dr. T.P. Snutch [I?]. 
To~al mRNA was cxtractcd from rat subslantia nigra using lhc 
method of Chomcynsky and Sacchi [I 31. Firsi-strand synrhcsis of 
cDNA was perrormcd using a cDNA synrhcsis kit (Invilrogco) xc- 
cording lo 1l1c supplier’s instructions. cxccpr that mRNA was printed 
with a dcgcrterittc Elmer oligonuclcotidc dcrivcd from the alignment 
of ~hc sixth tnmsmcmbranc (TM 6) scgmcnl of lhc rat GABA lr;1ns- 
porlcr and humitn NA transporter [&!I]. ATCTG(A/G)GT(G/ 
T)GCGGCWG)TCIA(T/GIC (Primer A) at iI linal conccmration oT 
4dO nM. Ddcblc:strundcd &!I; U’;IS syn&sizcd and amplilicd using 
2.5 U Taq Polymcrasc (Ceius) and 75 nM primers A and B (AA(C/ 
T)GT(GIA)TGG(AiC)G(GIC)TTCCClTA. dcrivcd from rhc conscn- 
sus ;dignmclll of TM I (as above) in 50 ~1 or IO mM Tris-HCI. ?H 
8.3. 50 IL&I KCI. I.5 mM M&I.. 0.5 mM dNTP. 0.5 mM dilhiotbre- 
itol und 0.01% gelatin. ror 30 cycles at 93°C for I min. 50°C Ibr I min. 
,;md 7PC f’or 80 s. cndcd by 12 min al 73OC. The producls or ibis 
~wctio~l wcrc resolved on a 1% agarosc gel and ~hc cDNA ranging 
rrom 500-800 hp WIS cxtractcd (Gcnc-clean. RIO 101) and an aliquol 
rc-amplilicd using primers C. located in TM 6 (TACGAATTCTG(Ai 
G)GT(GTT)GCGGC(AIG)TCIATCCA) and D, localcd in Thl I 
(GCCGAATTCAA(CIT)GT(G/A)TGGAGGTTCCCITA) For 30 cy- 
cles at 94°C for I min. 54°C Ibr 45 s, and 72°C f’or 80 s. ended by I2 
nun at 72°C. Thcsc primers each contained EcoRI rcslriction &es. 
The cDNA oblaincd (~700 bp) was then digcslcd with EcoRI and 
subcloncd inlo pBlueScrip1 (Stralngcnc) both for sequencing end syn- 
llicsis oT cRNA probes. 
For uptake cxpcrimcnts, the DMEM medium was replaced by 5 
mM Tris-base. 7.5 mM HEPES. 140 mM NLCI. 5.4 mM KCI. I .8 mM 
CaCI,, 0.8 mM MgSO,. I mM ascorbic acid. 5 mM D-~IUCOSC. final 
pH 7. I (uptake burrcr). AI thccnd ofthc incubation.cclls wcrc washed 
3-times in the uptake bufrer containing 0.5 aM nomil’cnsinc. and then 
resuspended in 0.5 mi or 0.1 S NzOH for ! h. A!! a!lquot was then 
taken for scintillation counting. For dctcrmination of inhibition of 
uptake. cells u’crc incubated 2 min with thcdrug IO be tcstcd. and then 
I5 n&l of ‘H.dopaminc was added in a linal volume of 0.5 ml Tar 5 
min. To detcrminc 111~ Na‘ dependency. KKI was substituted with 
IJO mM LiCI. The Ki values wcrc dcvrmincd using the EBDA and 
LIGAND programs [17]. 
23. PCR-/r!r.scr/ l;lwc~r~~ .wcwri~~~ 3. RESULTS AND DISCUSSION 
Two spccilic primers. E (TGCCCTACCTGCTCTTCATGG. nu- 
clcolides 299-318 on Fig. I) and F (GCCCAGGTCATCAATGCCA- 
C. nucleolidcs 680-699 on Fig. I) wcrc dcsigncd from the sequence of 
clone PCT?;md used IO umpliry ~hc DNA From I5 batches comprising 
citch I50 000 individual clones IIom a high molecular weight- cnrichcd 
cDNA library rrom IOI;II brain, constructed in ZAP [Is]. One ofthese 
smnplcs rc~C;tlcd the presence of a spccilically imiplilicd marcrial, imd 
ihc I50 000 slarling clones rrom this bntch wcrc split inlo 25 rraclions 
0r -10 OirO pru, among which one rraclion was positive again d-b3 
PCR amplilication. The lambda clones were then plated and lilicd 011 
ni\roccllulosc filters (Schlcichcr and Schlucll), and hybridized with iI 
nick-transl;ttcd probe obtained from PCT2, as described clscwhcrc 
[14J. The pUlucScript was cxciscd Tram ~hc puriflcd phagc. and iI 2.2 
The recent cloning and moleculnr characterization of 
specific transporter proteins for the neurotransmitters 
GABA and NA has revealed the emergence of a novel 
family of transmembrane proteins with simiiar putative 
topography and significant amino acid identity [8,9]. 
Since NA and dopamine are both catecholamines, it 
may be expected that a specific dopamine transporter 
may share significant homology with both the GABA 
and NA transporters. To test this hypothesis, and at- 
tempt to isolate a putative dopamine transporter, a set 
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kb Fragmcnl was scqucnccd and subcloncd inlo pCMV5 [IS) For cx- 
prcssion. Screening of a Surr3A par:ial rat gcnomic library (Strata- 
gcnc) and rat gcnomic Southern blot analysis with a nick-translated 
probe from clone PCTl were pcrrormcd as described 1141. 
The PCT?. clone which cncodcs sequences orthe transporter protein 
liom the putative TM I IO TM 6 ligated imo the EcoRl site of 
pBlueScrip1 was used IO synthesize scnsc and antisense strand cRNA 
probes. Uridinc 5’-([a-“%]lhio)triphosphatc-labclcd probes wcrc px- 
pared by in vitro transcription of circular templates with T7 and T3 
RNA polymcrascs, IO a specific aclivily of S-IO” cpm.pg’. In situ 
hybridizrtton was conducted as previously described IIG]. Briefly, 
rrozcn rat brain sections wrrc thawed and fixed for IO min in 4% 
paraformaldchydc with phosphate burrercd saline at 4°C. Sections 
wcrc hybridized with heat-dcnaturatcd probes (3-5x10” cpm.ml-r) 
and trcatcd with RNasc A at 50 pg .ml-‘. Sections were washed in 4 
I ol’ 0.1X standard saline citrate, 14 mM 2.mercaptocthanol. 0.05% 
sodium pyrophosphate Tar 3 h at 55-58’C and cooled IO room 
rcmpcraturc gradually over 12-16 h. Slides wcrc exposed at -80°C to 
Kodak XAR Rim for 6 days. 
African green monkey kidney (COS-7) cells wcrc transiently trans- 
fizctcd with a pCMV5-TS3 construct using the lipofcciinc mcthod 
(Gibco BRL) in i?-well (issue culture plates (?I-mm diameter) accord- 
ing to the supplier’s instructions. In briel; each well containing4-5x10’ 
subconllucnt COS-7 cells \vas washed 3-times with 0.5 ml or serum- 
Free DXIEM medium bcrorc adding I5 ~1 of a mixture containing 0.5 
,LQ DNA and 5.&r liporcctinc. Aficr 5-7 h incubation at 37°C. the wells 
were supplcmcntcd with an additional 0.5 ml DMEM medium con- 
taining 20% Octal bovine strum and the antibiotic gentamycin (IO 000 
UA)and incubated an additional 48 h a~ 37’C in a 5% CO2 incubator. 
Fig. I. Nuclcotidc und deduced amino acid scqucnccs or the rat ‘IS3 clone. Nuclcolidcs and amino acids arc numbcrcd (right side) consecutively 
I’rom IIIC pulative translation initiation codon. Solid bars rcprcscnl pulalivc transmcmbranc domains. Cross-halchcd tr;lrs indicate consensus sites 
t-or Wglyeosylarion. Asterisks indicalc polcmial shcs oT protein kinasc A and C phosphorylation on prcsumcd inlrilcellular domains. Arrows 
indicdlc ~hc localion or hitron-cxon junctions mapped from IIIC partial scqucncc or a ral gcnomic clone. 
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Fig. 7. Localization of the dopaminc transporter mRNA in rat brain 
by in situ hybridization. Consecutive coronal sections (Bregma-5) 
were incubutcd with cRNA prob:s i :: ::?e antiscnsc (A) and sense (B) 
orientation as dcscribcd in section 1. SNC: suhstantia n&a pars com- 
pacta: VTA: ventral tcgmental arca. No positive signal was obxrvcd 
in other sections at the level of the caudarc putameu and nucleus 
accumbens. arcas where functional dopaminc uptake is present. 
of degenerate primers derived from conserved sequen- 
ces among the GABA and NA transporters in the first 
(primers B and D. nucleotides 244-264 in Fig.’ 1) and 
slxtli (primers A and C, nticleotidcs 948-925 in Fig. 1) 
TM were synthesized and used for PCR amplification 
(see Materials and Methods). To increase the probabil- 
ity of anplifying a dopamine transporter, we used as 
template mRNA from substantia nigra, a brain nucleus 
which mainly comprises dopaminergic cell bodies. 
Among the clones obtained, one (PCT2) displayed a 
high level of identity in its nucleotide sequence both 
with the human NA (70%) and rat GABA (66%) trans- 
porters. 
In an attempt to isolate a full length cDNA clone, a 
PCR-based !ibrary screening approach was used. Two 
specific oligonucleotides (primers E and F) were synthe- 
sized based on the sequence of PCT2 clone, and em- 
ployed to amplify DNA from a cDNA library (see Ma- 
terials and Methods). Three identical clones (TS I, TS2 
and TS3) were finally isolated by plaque hybridization, 
and their 2.2 kb cDNA insert used for sequencing and 
expression in mammalian cells. The nucleotide and de- 
duccd amino acid sequence of clone TS3 is shown on 
Fig. 1. An open reading frame for a putative protein of 
620 residues (M, 69 029) starts with methionine at base 
1 and extends to b;lse 1860 (Fig. 1) which is followed by 
a stop codon. The methionine tentatively assigned as the 
start of translation for this protein was chosen on the 
basis that it conformed to the Kozak consensus se- 
IS2 
0 2D 45 65 
Time (mln) 
A GBR12763 
Q GBR 12909 
l Nomilensine 
A d-arrqhelamine 
n Norodrenaline 
-log [Competitor] (M) 
Fig. 3. Pharmacological characterization 01’ thr: cxprcsscd dopaminc 
transporter in COS-7 cells. (A) Time-course or dopaminc uptake. 
Cells were incubated as dcscribcd in section 2 with I5 IIM >H-dopa- 
mine.(B) Competition ol“H-dopaininr-uptake by various ncurotrans- 
mittcrs and ~~ptnlic blockers. Rcsuhs arc the nmm of tripliute dctcr- 
minations horn a sin& cxpcrimcnt snd arc rcprescnhtivc of Z-3 
sitnilur dctcrminations. 
quence [!8]. Although no in-frame stop codon could be 
identified in the 12 bp 5’ upstream of this putative start 
site. the protein sequence matches fairly we!! with that 
of other members of this protein family. Hydropathicity 
analysis (not shown) of the deduced amino acid se- 
quence suggests that this protein comprises 12 stretches 
of 22-24 amino acids (underlined in Fig. I) that may 
represent transmernbrane spanning domains. Tlte dc- 
duced sequence indicates the presence of 4 putative sites 
for jV-glycosylation, a!! contained within the sequence 
which lies between proposed TM 3 and TM 4. The lack 
of a readily identifiable signal sequence peptidc suggests 
that the N-terminal segment of tile protein resides on 
the cytoplasmic side of the plasma membrane. These 
various features of the protein encoded by this TS3 
clone strikingly resemble the molecular properties of 
transporter proteins for GABA and NA [8,9]. 
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To determinate initially whether the isolated PCT2 
clone might represent a specific transporter for the bio- 
genie amine dopamine, in situ hybridization was per- 
formed on rat brain sections. In the central nervous 
system (CNS) dopamine is mainly synthesized in the 
substantia nigra pars compacta (SNC, A9) and in the 
ventral tegmental area (VTA, AlO). Fig. 2A shows that 
an antisense cRNA probe synthesized from the PCT2 
clone hybridizes selectively to hoth the SNC and the 
VTA on coronal brain sections. In Fig. 2B the same 
experiment was repeated on a consecutive section with 
a sense cRNA-label!ed probe. I_!nder these conditions 
no radiolabelling of the A9 and A 10 dopaminergic neu- 
rons was observed thus confirming the specificity of the 
signal observed in Fig. 2A. Thus, the distribution of the 
mRNA encoding for this protein is consistent with it 
being a dopamine transporter. 
To confirm the identity of this presumed dopamine 
transporter, transient expression of the protein was ex- 
amined in COS-7 cells using the 2.2 kb cDNA clone 
subcloned into pCMVS. As shown in Fig. 3A expres- 
sion of the cDNA established in these cells a time- and 
sodium- dependent uptake of dopamine. At that con- 
centration of dopamine (15 nM) a plateau was reached 
between 20-30 min. The uptake of dopamine was spe- 
cifically blocked by the uptake blocker, nomifensine, or 
in the absence of Na’+ (i.e. presence of Li’). The K,,, for 
dopamine uptake was ~300 nM. The ability of several 
neurotransmitters and uptake blockers to compete for 
.the uptake of dopamine by transfected COS-7 cells was 
determined (Fig. 3B and Table I). The selective dopa- 
mine uptake blockers GBR-12783 [19], GBR-12909 [2.!J] 
and mazindol, were the most potent competitors of up- 
take. Nomifensine and cocaine showed intermediate le- 
vels of potency. D- and i-amphetamine showed about 
a IO-fold stereoselectivity in their ability to decrease 
‘H-dopamine-uptake. Several other compounds listed 
in Table I, like the tricyclic anti-depressants, nortrypti- 
line or desipramine, displayed Ki values greater than I 
,uM for inhibition of uptake, as expected [21]. Note- 
worthy is the fact that the Ki value for cocaine is similar 
to that which has been reported previously for the clo- 
ned human NA transporter (300 vs. 150 nM) [9]. Nora- 
drenalinc has a Ki of 10,~M at this cloned transporter, 
a value significantly greater than that which has been 
previously reported for the 3H-dopamine transporter in 
rat brain (1 PM) [22]. Thus, the pharmacological profile 
of the uptake of dopamine by transfected COS-7 cells 
confirms the identity of this protein as a dopamine 
transporter protein. 
Comparison of the amino acid sequence of this rat 
dopamine transporter with the sequence of the previ- 
ously cloned GABA and NA transporters reveals a sig- 
nificant degree of amino acid conservations. The rat 
dopamine transporter is 64% identical to the human NA 
transporter and 30% to the rat GABA transporter. 
These identities are even more pronounced when com- 
Table 1 
Pharmacology of the rat dopamine transporter expressed in COS-7 
C&S 
Compound K,(nhl) Hill coefficient 
GBR 12783 I1 0.83 
GBR 12909 12 1.28 
Mazindol 27 1.12 
Nomifensine II8 0.81 
Dopamine 316 1.38 
Cocaine 336 0.83 
D-Amphetamine 881 0.93 
L-Amphetamine 9590 1.29 
6-OH-Dopamine ZIOOO nd 
Reserpine >I000 nd 
Epinephrinc >I000 nd 
Norepinephrine 5 10,000 nd 
Histamine 21n.000 nd 
Amitryptiline > 10.000 nd 
Dcsiprnmine 5 I0.000 nd 
GABA > I0,000 nd 
Serotonin > 10,000 nd 
COS-7 cells were transiently transfccted with a pCMV5-TS3 construct 
as described in Materials and Methods. Dopaminc uptake was mcas- 
wed in the presence of I5 nM JH-dopamine and at least 6 conccntra- 
tions of each compound as listed. Each point represents the mean of 
3 similar cxpcrimcnts. nd, not determined. 
paring sequences within the putative transmembrane 
domains (74% with NE and 49% with GABA transpor- 
ters). An alignment (not shown) of the amino acid se- 
quences of this dopamine transporter with those for the 
NA and GABA transporters hows that these 3 proteins 
obviously belong to the same family of proteins. Their 
amino- and carboxyl-terminal domains are of similar 
!engths. Various intra- and extracellular connecting 
loops display similar sizes. In addition, specific motifs 
appear to be conserved, as there are a total of 217 amino 
acids that are invariant between all 3 proteins. 
Preliminary experiments indicate that the gene for 
this rat dopamine transporter will display the usual 
complex structure of eukaryotic genes. Partial sequenc- 
ing of the rat genomic clone revealed the presence of at 
least 2 introns in this gene (indicated by the arrow heads 
in Fig. 1). The complexity of the gene structure for this 
transporter is confirmed by the resuits of genomic 
Southern blot analysis (Fig. 4). Using several restriction 
enzymes on rat genomic DNA probed with the PCT2 
clone, multiple hybridizing bands were obtained even 
for restriction enzymes for which no restriction sites 
exist in the cDNA (all but BgnI) (Fig. 4, legend). 
The cloning of a cDNA for a dopamine transporter 
indicates that a single polypeptidc chain is capable, 
when expressed into a host cell, of recapitulating the 
function of the CNS dopamine transporter with appro- 
priate pharmacological characteristics and dependence 
on Na’. The distribution of the mRNA for lhis trans- 
porter protein in the areas of dopaminergic cell bodies 
suggests that this protein may be the main component 
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Fig. 4. Southern blot of rat gcnomic DNA. Ra1 gcnomic DNA (IO 
/@lane) was digcsied with the restriciion enzymes shown. subjeclcd 
IO agarosc gel clec1rophorcsis. blo11cd onto nilroccllulosc and probed 
with 1hc PCTZ clone. The fihcr was washed in ?x SSC, 0.1% SDS. 
two-times ror I5 min ai 37°C and hen 0. lx SSC. 0. I% SDS for 15 min 
at 37 and 45°C. consccuiivcly. The aulorddiogram was developed ror 
48 h. The posi1ion oTmolccular wcichi standards are indica1cd on 1hc 
righi. The PCT2 probe did not co&n rcs1riction silts For any cnzymc 
cxcrpl Dgili (I site). 
for the termination of dopaminergic neurotransmission. 
In vitro arid in vivo pharmacological studies have sug- 
gested that this transporter can interact Ah several 
classes of neurotransmitter-uptake inhibitors [23]. The 
most weil known example of this wou!d be the interac- 
tion of this transporter with the substance of abuse, 
cocaine. Indeed, the rewarding and addictive effects of 
cocaine administration seem to be mediated by its inter- 
action with a dopamine transporter in dopaminergic 
innervated areas of the CNS. Thus. the elucidation of 
the structure of this transporter should facilitate studies 
of the structure and function of drugs that interact with 
this transporter or into the mechanisms mediating re- 
ward and addiction to substances of abuse. In addition, 
since the function of dopamine is impaired in many 
neuropsychiatric disorders, the availability of probes 
for a dopamine transporter may help in assessing 
whether the gene for this transporter might bear rela- 
tions to the etiology of these disorders. 
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